300110 华仁药业
2026/03 - 三个月2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)1.887-43.289-68.5127.1997.375
总资产报酬率 ROA (%)0.581-15.102-31.8483.6423.346
投入资产回报率 ROIC (%)0.732-18.134-35.8444.0263.818

边际利润分析
销售毛利率 (%)33.24937.04535.20242.72343.272
营业利润率 (%)7.390-34.484-99.98713.80912.256
息税前利润/营业总收入 (%)9.583-31.529-96.13817.95916.754
净利润/营业总收入 (%)5.421-34.764-100.71511.82111.195

收益指标分析
经营活动净收益/利润总额(%)101.623-25.492-6.118100.402108.010
价值变动净收益/利润总额(%)-0.221-1.0490.0860.366-0.673
营业外收支净额/利润总额(%)-14.0800.7070.2041.9833.579

偿债能力分析
流动比率 (X)0.8200.6740.7661.8411.345
速动比率 (X)0.6380.5100.5601.6201.214
资产负债率 (%)66.78766.35659.92246.45549.645
带息债务/全部投入资本 (%)59.23458.73454.55641.40041.876
股东权益/带息债务 (%)65.08866.43880.605139.113129.542
股东权益/负债合计 (%)45.86146.73263.324112.26698.742
利息保障倍数 (X)3.086-9.850-23.7174.6394.144

营运能力分析
应收账款周转天数 (天)142.798137.650157.117142.065160.014
存货周转天数 (天)105.969121.111134.024115.520106.255